SCHEMBL4537362

SCHEMBL4537362

CCC(C)(C)S(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
MMP1 P03956 1/20 0.51
MMP2 P08253 1/20 0.51
MMP9 P14780 1/20 0.51
MMP8 P22894 1/20 0.51
MMP13 P45452 1/20 0.51
CYP3A4 P08684 3/20 0.46
CYP2C19 P33261 3/20 0.46
CYP2C9 P11712 2/20 0.45
CYP2D6 P10635 1/20 0.45
TRPV1 Q8NER1 1/20 0.44
NPSR1 Q6W5P4 2/20 0.44
PPARG P37231 1/20 0.44
HDAC3 O15379 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HTT P42858 2/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12688536 0.86 CA1 (0.54) CA1CA2MMP1MMP2MMP9
SCHEMBL1498475 0.86 CA1 (0.50) CA1CA2MMP1MMP2MMP9
SCHEMBL1498465 0.86 CA1 (0.50) CA1CA2MMP1MMP2MMP9
SCHEMBL1498482 0.84 CA1 (0.53) CA1CA2MMP1MMP2MMP9
SCHEMBL1498474 0.84 CA1 (0.53) CA1CA2MMP1MMP2MMP9
SCHEMBL12689083 0.83 CYP3A4 (0.49) CA1CA2MMP1MMP2MMP9
SCHEMBL1498512 0.83 CA1 (0.57) CA1CA2MMP1MMP2MMP9
SCHEMBL1498446 0.82 CA1 (0.50) CA1CA2MMP1MMP2MMP9
SCHEMBL1498491 0.82 CA1 (0.50) CA1CA2MMP1MMP2MMP9
SCHEMBL12688534 0.81 CA1 (0.46) CA1CA2MMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120316173-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-13 US disclosed
WO-2012061926-A1 BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120316173-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR CNR2, CNR1, OPRL1 CA1 3309/4885CA2 1903/4885MMP1 3553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.